ロード中...
Comparison of extended to standard half-life recombinant factor VIII therapy in patients with hemophilia A on prophylactic therapy
Background: Hemophilia A is a genetic bleeding disorder caused by a deficiency in factor VIII (FVIII). FVIII maintains bleeding homeostasis within the body through its downstream effects on the intrinsic clotting cascade. The extent of the disease – mild, moderate or severe – depends on the amount o...
保存先:
| 出版年: | J Drug Assess |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6764360/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21556660.2019.1658327 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|